Drug Type Autologous CAR-T |
Synonyms LMY 920, LMY-920 |
Target |
Mechanism BAFF inhibitors(B-cell-activating factor/B lymphocyte stimulator inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Luminary Therapeutics, Inc.Startup |
Active Organization Luminary Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Systemic Lupus Erythematosus | Phase 1 | - | Luminary Therapeutics, Inc.Startup | 01 Jun 2024 |
Plasma cell myeloma refractory | Phase 1 | US | Luminary Therapeutics, Inc.Startup | 13 Mar 2024 |
Relapse multiple myeloma | Phase 1 | US | Luminary Therapeutics, Inc.Startup | 13 Mar 2024 |
Non-Hodgkin's lymphoma refractory | Phase 1 | US | Luminary Therapeutics, Inc.Startup | 21 Nov 2023 |
Recurrent Non-Hodgkin Lymphoma | Phase 1 | US | Luminary Therapeutics, Inc.Startup | 21 Nov 2023 |